Amgen Patent-Cliff Exposure & CMS Drug Spending Portfolio
Amgen (Thousand Oaks, CA): 48 reconciled FDA prescription therapies (16.4% 2025 to 2030 cliff risk), $11.90B 2024 CMS Part D & Medicaid spend, and 192 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Thousand Oaks, CA |
| Reconciled FDA Portfolio Therapies | 48 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 16.4% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $11.90B |
| 2024 Medicare Part D Spend | $8.55B |
| 2024 Medicaid Spend | $3.34B |
| California HCAI SB 17 Filings | 192 WAC filings (max 31.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.